Trial Profile

A Phase 1b Dose-escalating Study With RBT-1 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Dec 2021 Number of treatment arms have been increased from 7 to 9, by the addition of cohort 8 (Dose H, single dose) and 9 (Dose I, single dose), comprising Subjects with CKD Stage 3 or 4. Primary outcome measure has been changed from Effect of RBT-1 on biomarkers to Safety and tolerability thus shifting trial focus from PD to AR.
25 Feb 2021 According to a Renibus Therapeutics media release, data will be presented at the Acute Kidney Injury & Continuous Renal Replacement Therapy (AKI & CRRT) 2021 Conference.
15 Sep 2020 Planned End Date changed from 31 Aug 2020 to 31 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com